We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+20.65%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$330M
AUM Growth
+$6.54M
Cap. Flow
+$45.9M
Cap. Flow %
13.92%
Top 10 Hldgs %
38.17%
Holding
104
New
22
Increased
33
Reduced
18
Closed
24

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$17.8M
2
URGN icon
UroGen Pharma
URGN
+$8.17M
3
MRSN
Mersana Therapeutics
MRSN
+$7.61M
4
GOSS icon
Gossamer Bio
GOSS
+$7.06M
5
CBAY
Cymabay Therapeutics
CBAY
+$5.7M

Top Sells

Rank Stock Value
1
SDGR icon
Schrodinger
SDGR
+$10.3M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$10.2M
3
AKRO
Akero Therapeutics
AKRO
+$9.78M
4
KRYS icon
Krystal Biotech
KRYS
+$5.78M
5
ETNB
89bio
ETNB
+$5.64M

Sector Composition

Rank Sector Weight
1 Healthcare 81.31%
2 Consumer Staples 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMAM
101
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-100,000
Closed -$1.65M
FRTX
102
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
-10,000
Closed -$7.01K
RETA
103
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-12,500
Closed -$1.27M
VRAY
104
DELISTED
ViewRay, Inc.
VRAY
– –
-100,000
Closed -$35.2K
1 2 3 4
5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Silverarc Capital Management held 104 positions worth $330M, up 2% from $323M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Silverarc Capital Management deployed $45.9M of net new capital in Q3 2023, opening 22 new positions and adding to 33 existing holdings. Its largest new stake was UroGen Pharma: 508,883 shares worth $7.13M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Schrodinger, an estimated $10.3M trimmed.

  • Silverarc Capital Management's largest Q3 2023 buy was UroGen Pharma: 508,883 shares worth $7.13M.
  • Silverarc Capital Management added most to Morphic Holding, Inc. Common Stock in Q3 2023, an estimated $17.8M increase.
  • Silverarc Capital Management's biggest Q3 2023 reduction was Schrodinger, cutting an estimated $10.3M.
  • Silverarc Capital Management fully exited MoonLake Immunotherapeutics in Q3 2023, selling an estimated $10.2M.
  • Silverarc Capital Management's ten largest holdings make up 38% of its $330M portfolio in Q3 2023.
  • Silverarc Capital Management opened 22 new positions and closed 24 in Q3 2023.
  • Silverarc Capital Management's portfolio value rose 2% quarter-over-quarter to $330M.

Based on Silverarc Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.